While the CD16 reduction in expression within the ovarian tumor microenvironment may impact the ADCC mechanism of the TriKE, and the therapeutic antibodies, it has been shown that localization of IL-15 at the site of the tumor results in enhanced NK cell activity against the tumor and tumor clearance [41]. The gene discussed is IL15; the disease is neoplasm.